1 / 1

HCC5-1318

HCC5-1318. A. Days during treatment. B. C. Foretinib. Foretinib. Vehicle. (15mg/kg). (30mg/kg). *. **.

caelan
Download Presentation

HCC5-1318

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HCC5-1318 A Days during treatment B C Foretinib Foretinib Vehicle (15mg/kg) (30mg/kg) * ** Fig 2S Effects of foretinib on tumor growth of patient-derived xenograft line 5-1318. 5-1318 tumors were s.c implanted in SCID mice as described in Materials and Methods. Mice bearing tumor xenografts were treated with vehicle (30% Captisol) or 2 doses of foretinib: 15 mg/kg (daily) and 30 mg/kg (every other day) for 14 days as described in Materials and Methods. Each treatment arm involved 14 independent tumor-bearing mice. Mean of tumor volume ± SE at given time points (A), representative vehicle- and foretinib-treated tumors (B) and the corresponding tumor weight and statistical analysis (C) for 5-1318 xenografts are shown. Different asterisks (*) indicate significantly different from one another at P <0.05. Experiments were repeated twice with similar results. + - - Vehicle - 15 30 Foretinib (mg/kg)

More Related